Redeye retains its positive view on q.beyond, maintaining our Base Case at EUR 1.
Endomines production in Q4 was weaker than expected, but further gold price momentum continues to ca...
At SEB’s Nordic Seminar, CFO Per Brilioth discussed the milestones VNV achieved during 2025, includi...
Redeye lowers its forecasts and Base Case slightly, which, however, remains substantially above the ...
The UK and Germany signal uncertainty after management communicated in mid-December that it will not...
At SEB's Nordic Seminar, CFO Larsen highlighted how management spent 2025 broadly derisking the equi...
* Acquisition of Volvo Construction Equipment dealer in Iowa * Adds 8% to PF'26e EBIT, 13x acquisiti...
Redeye provides an update on Biovica following the Q2 2025/2026 report, which showed weaker-than-exp...
Aneo has completed its recommended public cash offer and now controls approximately 92.
We expect Duell’s sales and adjusted EBITA to both decline y/y in Q1.
Redeye initiates coverage on Hacksaw, a fast-growing and highly profitable Remote Gaming Server (RGS...
Redeye comments on SSH Communications Security's profit warning issued today, where the company lowe...
* Market conditions remain challenging, lowering Q4e volumes * We lower '25e-'27e adj.
Redeye briefly comments on Alligator Bioscience announcing the outcome of its rights issue, with 64.
* Rights issue of SEK 51.8m to accelerate recycling expansion * Fully covered by subscription and un...
In a decision published today by the Swedish Competition Authority, we find that they have concluded...
Redeye comments on Litium’s announcement of a strategic partnership with Monitor ERP, where Litium b...
Redeye has changed lead analyst of Cheffelo and provides a preview ahead of the company’s Q4 report ...
Redeye notes that it now appears beyond all reasonable doubt that Novartis will not initiate any lit...
Redeye updates on Vitrolife after a site visit and a change of lead analyst.